Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera Heart dd-cfDNA Test for Heart Transplant Recipients - Seite 3

About Natera

Natera^TM is a global leader in cell-free DNA testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 180 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit www.natera.com.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, or our expectations of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.

References

1. Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2022 Annual Data Report: Heart. U.S. Department of Health and Human Services, Health Resources and Services Administration. 2024. Accessed April 4, 2024. https://srtr.transplant.hrsa.gov/annual_reports/2022/Heart.aspx#fig:HR ...
2. Bermpeis K, Esposito G, Gallinoro E, et al. Safety of right and left ventricular endomyocardial biopsy in heart transplantation and cardio-myopathy patients. JACC Heart Fail. 2022;10:963–973.
3. Strecker T, Rösch J, Weyand M, et al. Endomyocardial biopsy for monitoring heart transplant patients: 11-years-experience at a German heart center. Int J Clin Exp Pathol. 2013;6:55–65.
4. Deckers JW, Hare JM, Baughman KL. Complications of transvenous right ventricular endomyocardial biopsy in adult patients with cardio-myopathy: a seven-year survey of 546 consecutive diagnostic procedures in a tertiary referral center. J Am Coll Cardiol. 1992;19:43–47.
5. Hamour IM, Burke MM, Bell AD, et al. Limited utility of endomyocardial biopsy in the first year after heart transplantation. Transplantation. 2008;85:969–974.
6. Hull JV, Padkins MR, Hajj SE, et al. Risks of right heart catheterization and right ventricular biopsy: a 12-year, single-center experience. Mayo Clin Proc. 2023;98:419–431.
7. Cusi V, Vaida F, Wettersten N, et al. Incidence of Acute Rejection Compared With Endomyocardial Biopsy Complications for Heart Transplant Patients in the Contemporary Era. Transplantation. 2023. Epub ahead of print. PMID: 38098137.